UGA researchers discover how human body fights off African parasiteSeptember 07, 2007Research could lead to new methods of controlling similar parasites that cause endemic diseases Trypanosoma are a nasty class of single-celled parasites that cause serious, even fatal, diseases in human and animals. Two species cause sleeping sickness, a disease that threatens all of sub-Saharan Africa. There's a catch though: one parasite, Trypanosoma brucei brucei (T. b. brucei), infects animals but seems to spare humans, and scientists haven't quite understood why. Now, a team of researchers led by biochemists at the University of Georgia propose that T. b. brucei actually does infect humans but that the infection triggers release of hemoglobin from red blood cells. Hemoglobin appears to "arm" the human innate immune system by binding to a small fraction of high density lipoprotein (HDL), or "good cholesterol." The hemoglobin-HDL complex then becomes a super toxin and clears the body of trypanosomes. "This is a real paradigm shift in understanding what T. b. brucei does in humans," said Stephen Hajduk, professor and head of the department of biochemistry and molecular biology at the University of Georgia. "It had always been assumed that it didn't infect humans at all, but it now appears that it does and that the release of free hemoglobin leads to clearance of the infection. It was incredibly surprising to us." Lead author on the research is Justin Widener, a graduate student in Hajduk's lab. The research was published today in the Public Library of Science Pathogens. Widener is also a student at Brown University, where he began his work with Hajduk, who joined the UGA faculty in 2006. Other authors on the paper include April Shiflett of UGA and Marianne Jensby Nielsen and Søren Krag Moestrup of University of Aarhus in Denmark. Hajduk and his group are interested in a parasite that does not harm humans because they asked a simple question: why can't T. b. brucei infect humans although it is nearly identical to the African sleeping sickness-causing parasite" After all, two cousins of T. b. brucei, known as T. b. gambiense and T. b. rhodensiense, cause, respectively, chronic and acute sleeping sickness in humans. The parasites, which are carried by the tsetse fly and injected into humans and animals with its bite, have been a major health issue since the first recorded outbreak of sleeping sickness beginning in 1906. "We know that humans are protected against T. b. brucei by the action of a high-density lipoprotein called Trypanosome Lytic Factor [TLF]," said Widener. "We investigated the mechanism of how TLF kills the parasite by using a purification technique that allowed us to show that a protein associated with TLF strongly binds hemoglobin and that hemoglobin stimulates TLF to kill the parasite." Because all three strains are closely related-T. rhodensiense is different from T. b. brucei by a single gene-what is true for one species could be useful in understanding the others. While human sleeping sickness has been an important human disease in Africa for more than a century, recent epidemics of the disease in five African nations underscore the potential threat of this disease to travelers and aid workers. One interesting aspect of trypanosomes is their ability to infect a wide range of mammals, from humans to wild game. The severity of disease caused by T. b. brucei varies depending on the host; infections in humans are cleared while a fatal disease develops in infected cattle. The application of the discovery by Widener on the mechanism of human protection may lead to better treatment of cattle infections by these parasites. The value of the new research may lie as much in its potential as a model system for studying all trypanosomes as it does in specifically understanding why T. b. brucei doesn't infect humans. University of Georgia |
|||||||||||||||||||||
| Related Sleeping Sickness Current Events and Sleeping Sickness News Articles Possible help in fight against muscle-wasting disease A compound already used to treat pneumonia could become a new therapy for an inherited muscular wasting disease, according to researchers at the University of Oregon and the University of Rochester School of Medicine and Dentistry in New York. How much is the world spending on neglected disease research and development? The first comprehensive survey of global spending on neglected disease R&D, published in this week's PLoS Medicine, finds that just over $US 2.5 billion was invested into R&D of new products in 2007, with three diseases-HIV/AIDS, TB, and malaria-receiving nearly 80% of the total. Scans show immune cells intercepting parasites Researchers may have identified one of the body's earliest responses to a group of parasites that causes illness in developing nations. DNA chunks, chimps and humans Researchers have carried out the largest study of differences between human and chimpanzee genomes, identifying regions that have been duplicated or lost during evolution of the two lineages. Death by hyperdisease It took less than a decade for native rats to become extinct on the Indian Ocean's previously uninhabited Christmas Island once Eurasian black rats jumped ship onto the island at the turn of the 20th century. 'Deadly dozen' reports diseases worsened by climate change Health experts from the Wildlife Conservation Society today released a report that lists 12 pathogens that could spread into new regions as a result of climate change, with potential impacts to both human and wildlife health and global economies. New UNC laboratory to help track and control tropical diseases The University of North Carolina at Chapel Hill School of Public Health has established a new Gillings Innovation Lab to track and map tropical infectious diseases such as malaria, using state-of-the-art molecular and demographic methods. Sleeping sickness finding could lead to earlier diagnosis Sleeping sickness creates a metabolic 'fingerprint' in the blood and urine, which could enable a new test to be developed to diagnose the disease, according to new research published today in the journal Proceedings of the National Academy of Sciences. New drug combination shows promise for African sleeping sickness A small clinical trial in Uganda, conducted within a long-established Médecins Sans Frontières (MSF) treatment program for African sleeping sickness, has found that a new combination treatment using the drugs nifurtimox and eflornithine holds promise and deserves further evaluation. Study finds multiple neglected tropical diseases effectively treated with drugs The neglected tropical diseases are a group of 13 infectious diseases, including elephantiasis, hookworm, African sleeping sickness and trachoma, which affect more than 1 billion people worldwide, most of whom live in extreme poverty. More Sleeping Sickness Current Events and Sleeping Sickness News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||